2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 15.611 | 17.155 | 13.845 | 18.948 | 19.820 | 19.037 | - | - | - | - |
Total Income - EUR | 15.619 | 17.167 | 13.847 | 18.969 | 19.847 | 19.075 | - | - | - | - |
Total Expenses - EUR | 2.000 | 2.796 | 2.011 | 2.004 | 632 | 126 | - | - | - | - |
Gross Profit/Loss - EUR | 13.619 | 14.371 | 11.836 | 16.965 | 19.215 | 18.949 | - | - | - | - |
Net Profit/Loss - EUR | 13.151 | 13.856 | 11.421 | 16.396 | 18.720 | 18.377 | - | - | - | - |
Employees | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
Check the financial reports for the company - Dankamed S.r.l.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Check Financial Rating2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Current Assets | 33.537 | 47.665 | 58.598 | 74.020 | 91.287 | 107.922 | - | - | - | - |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
Receivables | 522 | 895 | 1.061 | 241 | 3.246 | 232 | - | - | - | - |
Cash | 33.014 | 46.769 | 57.537 | 73.779 | 88.042 | 107.690 | - | - | - | - |
Shareholders Funds | 33.303 | 47.437 | 58.374 | 73.782 | 91.148 | 107.760 | - | - | - | - |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | - | - | - | - |
Debts | 233 | 227 | 224 | 238 | 139 | 162 | - | - | - | - |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8621 - 8621" | |||||||||
CAEN Financial Year | 8621 |
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Reports that can be accessed based on the subscription:
Get the contact details for any company and get in touch with it.